YUCAIPA, Calif., April 29, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading manufacturer of respiratory medical devices, recently announced that CEO, Scott Sand, will debut various new products in their medical product line, including: Oxyview, The SMART Nasal Cannula, and the new INGEN Pulse Oximeter, at the May 11th, 2010 televised Las Vegas Money Show, with host Steve Crowley from the Money Channel's renown American Scene broadcast. Ingen Technologies projects that the SMART Nasal Cannula will bring $10M in revenues, and the new INGEN Pulse Oximeter an additional $1M in revenues during 2010, and reach $200M over the next 5 years.
"Ingen is on the verge of tremendous growth, after enduring a number of regulatory and economic obstacles. In the face of economic headwinds, the company obtained both FDA and ISO Certification and launched several new and inspiring medical products in the respiratory market. As a result of this success, we have attracted many investors and new shareholders," stated Mr. Sand in a recent statement to the shareholders. He further stated, "Ingen has developed a global perspective on the markets in which we compete, inclusive of a thorough market study, securing valuable intellectual property, properly registering our products with the FDA and securing ISO 13485 Certification, CE Mark and distribution partners, in order to comply with the world markets for distribution of our medical products."
Ingen's recent successes and changes came during a restructuring in order to align incentives with that of its shareholders. The company is keenly focused on growth, open communication, and leadership by example, as it works diligently to expand its sales and deliver shareholder value.
"The Money Channel has been a very good investment for Ingen and its shareholders to discuss current events and the future of this company. It is a valuable tool that offers shareholders and new investors current information about what we have accomplished and where the company is headed. There is no question that we have strong financial backing to execute our share buy-back program scheduled in June, 2010, along with a very strong and active stock that is now demonstrating its potential. This new restructure is designed to take the company on to the Amex at a stock price of greater than $5.00 per share," stated Scott Sand, CEO and Chairman of the Board.
http://www.moneyshow.com/lvms/main.asp?scode=017566
http://www.smartnasalcannula.com/
http://www.ingenpulseoximeter.com/
About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472v
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.